5 Best Peptides for Uterine Fibroids

What to Know Before Choosing a Peptide for Uterine Fibroids

Uterine fibroids are benign smooth muscle tumors of the uterus, driven primarily by estrogen and progesterone. They are characterized by an unusually high collagen content, which makes them structurally dense and stiff, and by growth factor signaling involving IGF-1, TGF-beta, and EGF. That biology matters because it explains why different peptide classes approach this condition from completely different directions. Some aim at the hormonal axis that feeds fibroid growth. Others target the collagen and fibrotic tissue that makes up the bulk of the tumor. Still others are present because of their general tissue-repair and anti-inflammatory reputation, applied by community users hoping those properties carry over into reproductive tissue.

Every compound in this guide earned its place because people are using it or actively discussing it for fibroids, not because it holds a spotless clinical record. FDA approval status, trial depth, and regulatory category were not the filter. A compound backed only by community-reported experience belongs in this conversation when people are genuinely reaching for it. The honest approach is to include it and describe its evidence plainly, not to leave the reader with a list that quietly omits what they have already been reading about.

These five compounds are ordered by how prominently each appears in research and documented real-world use, not as a verdict on which is best for any individual. The right compound, if any, depends on your specific situation, your health history, and what you build with the help of a qualified clinician.

One important safety note belongs at the top: published laboratory research in PNAS found that a peptide called PrRP-31 increases proliferation in leiomyoma cells via the PI3K/AKT/MTOR pathway, a growth-promoting cascade, with that response absent in normal uterine tissue. That finding is a meaningful reminder that peptides interact with fibroid biology in ways that are not always intuitive, and that some compounds that sound relevant to this condition may actually promote growth rather than slow it.

1. Cetrorelix: The Only Peptide With Human Trial Data for Fibroids

Cetrorelix is a synthetic ten-amino acid GnRH antagonist, a peptide hormone that blocks the gonadotropin-releasing hormone receptor in the pituitary gland. When that receptor is blocked, the pituitary stops releasing FSH and LH, the hormones that signal the ovaries to produce estrogen and progesterone. Because fibroids depend on both of those hormones to grow, cutting off that signaling reduces the fuel supply.

What sets cetrorelix apart from every other compound on this list is that it is the only one with published human clinical trial data specifically for uterine fibroids. A Phase II trial found a statistically significant response compared to placebo, with measurable reduction in fibroid size achieved through lowering circulating estrogen. It has also been used as an adjuvant treatment before fibroid surgery, shrinking tumors to make procedures more manageable.

The clinical use comes with real constraints. Because cetrorelix works by inducing a low-estrogen state, it accelerates bone mineral density loss, a risk significant enough that treatment is capped at six months maximum. That limit reflects biology, not caution. Beyond the bone density concern, the hypoestrogenic state produces symptoms common to any medically induced menopause: hot flashes, headache, and mood changes. These come with the mechanism, not the molecule.

Cetrorelix is FDA-approved as a GnRH antagonist in fertility contexts and has been used off-label in fibroid research and clinical practice. It requires injection and physician oversight. It is worth noting that the broader pharmaceutical trend in fibroid management has moved toward oral, non-peptide GnRH blockers like elagolix and relugolix, which offer similar hormonal mechanisms without the need for injection and with add-back hormone therapy built in. Cetrorelix remains the standard-bearer among peptide-based options specifically because its evidence comes from trials in fibroid patients, not from extrapolation.

2. BPC-157: The Most Widely Discussed Experimental Option

BPC-157, or Body Protection Compound-157, is a synthetic fifteen-amino acid peptide derived from a protein found in gastric juice. It has a substantial preclinical track record in animal models for tissue repair, anti-inflammatory activity, and anti-fibrotic effects, which is why it became a fixture in community protocols for injuries and gut conditions long before it appeared in fibroid discussions. The crossover to fibroids is entirely community-driven: no clinical trials, no human data, and no fibroid-specific preclinical studies exist for BPC-157 as of 2026.

The theoretical rationale is straightforward. Fibroids are collagen-dense, fibrotic structures, and BPC-157 has shown anti-fibrotic properties in animal models. Pelvic inflammation is a common feature of fibroid symptoms, and BPC-157 has well-established anti-inflammatory effects in preclinical research. Neither of those facts constitutes evidence that BPC-157 shrinks fibroids or reduces heavy bleeding in humans, but they are the mechanistic bridge the community uses to justify the experiment.

What exists in practice is user-reported experience, primarily from online communities focused on women's use of peptides. Users have described reduced pelvic inflammation, eased pressure symptoms, and in one detailed account, a cessation of abnormal bleeding within approximately two weeks of starting a combined BPC-157 and TB-500 protocol. Critically, none of those accounts included imaging confirmation. No MRI, no ultrasound. The improvements described are symptom-based, and placebo effects, natural cycle variation, and the simultaneous use of multiple compounds make it impossible to draw conclusions from individual reports.

BPC-157 is sold as a research chemical and carries no regulatory approval for human therapeutic use. It is typically administered by subcutaneous injection in community protocols. General peptide therapy risks apply: injection site reactions, nausea, headache, and fatigue. For people with fibroids, the unknown interaction of BPC-157 with reproductive tissue and the theoretical concerns around growth factor signaling in peptide therapy broadly are reasons this sits firmly in the unvalidated category rather than among established options.

3. TB-500: The Anti-Fibrotic Stack Partner

TB-500 is a synthetic analog of Thymosin Beta-4, a naturally occurring protein involved in cell migration, tissue repair, and the regulation of inflammatory responses. Its primary mechanism is reducing fibrotic signaling by influencing how cells move and how tissue remodeling proceeds after damage. That anti-fibrotic action is the theoretical link to fibroids: since fibroids are defined by excessive extracellular matrix deposition and dense collagen, a compound that modulates fibrotic signaling becomes an obvious candidate for interest.

No human clinical trial data exists for TB-500 in uterine fibroids as of 2026. The preclinical evidence for its anti-fibrotic and tissue-repair effects comes from models of cardiac fibrosis, wound healing, and musculoskeletal repair, not from reproductive tissue studies. The application to fibroids is mechanistic extrapolation, not evidence of efficacy in this specific context.

In practice, TB-500 almost never appears alone in community fibroid discussions. It is paired with BPC-157 in nearly every protocol described online, to the point that users often treat the combination as a single compound. Community reports describing BPC-157 benefits for fibroid symptoms are frequently accounts of a combined protocol, which makes it impossible to attribute any observed changes to either compound individually. Understanding TB-500's role in fibroid discussions means understanding it primarily as a BPC-157 stack component rather than as a standalone option.

TB-500 is sold as a research chemical, requires reconstitution and subcutaneous injection, and carries no regulatory approval for human use in any therapeutic context. The evidence base for its application here is community-reported and indirect, drawn from general anti-fibrotic biology rather than from any fibroid-focused research.

4. GHK-Cu: The Collagen-Remodeling Rationale

GHK-Cu is a tripeptide (three amino acids: glycine, histidine, and lysine) complexed with copper. It occurs naturally in human plasma and is best known for its role in wound healing and skin regeneration, where it modulates both collagen synthesis and collagen breakdown. The connection to fibroids is purely mechanistic: fibroids are collagen-heavy structures, and GHK-Cu influences how the body produces and degrades collagen. Some practitioners and community members include it in broader fibroid protocols on the basis that shifting the balance of collagen turnover could theoretically affect the composition of fibroid tissue over time.

No direct evidence exists for GHK-Cu reducing or affecting fibroids in humans or in animal models specific to this condition as of 2026. The entire basis for its presence in fibroid conversations is the mechanistic logic of collagen remodeling applied to a collagen-dense condition. That logic is plausible enough to keep GHK-Cu in the conversation among practitioners exploring non-standard approaches, but plausibility is not the same as demonstrated efficacy.

GHK-Cu is available in injectable, topical, and oral forms. It appears in community multi-peptide fibroid protocols most often as a supporting compound rather than a primary one. Users typically describe including it for general tissue-balance and skin health benefits, sometimes noting that the fibroid rationale is speculative but worth exploring alongside other compounds. That framing is accurate: a mechanistic foothold in the condition's biology, without any validated outcome data for fibroids specifically.

5. Zhenoluten: The Tissue-Specific Bioregulator

Zhenoluten is a peptide bioregulator, a category also called cytamines, developed through Russian research into tissue-specific short peptides. It is formulated from uterine tissue extracts, typically of bovine or porcine origin, and is one of the very few compounds specifically marketed for female reproductive health conditions including uterine fibroids. That targeting is unusual: among the compounds in this guide, Zhenoluten is the only one labeled and sold for fibroid use rather than applied speculatively from another indication.

The theoretical framework behind peptide bioregulators, developed primarily by Vladimir Khavinson and colleagues, holds that short peptides derived from specific tissues regulate gene expression in those same tissues and can normalize cellular function that has become dysregulated. The uterus-derived peptides in Zhenoluten are proposed to act on uterine smooth muscle and support normal cellular behavior in tissue affected by fibrotic change. As a category, peptide bioregulators have a literature base in Russian scientific journals that largely does not overlap with Western peer-reviewed publication standards. No randomized controlled trials for Zhenoluten and uterine fibroids have been published in major Western journals as of 2026. The evidence base rests on the broader bioregulator framework, manufacturer claims, and Russian-language research that has not been independently replicated under Western clinical standards.

Zhenoluten is available in enteric-coated oral tablet form through specialty peptide suppliers, which distinguishes it from the injectable options in this guide and lowers the barrier to use for people who prefer non-injectable approaches. Its regulatory status varies by country; it is sold as a supplement or nutraceutical in some markets and is not FDA-approved as a drug for fibroid treatment. For readers considering it, the honest starting point is this: its appeal is specific uterine targeting and ease of administration, and its evidence base, while not entirely absent, has not been tested against the standards that would be required to support a therapeutic claim in most Western regulatory environments.

How These Peptides Compare

Frequently Asked Questions

Is there any peptide with actual human trial evidence for fibroids?

Yes, one: cetrorelix, a GnRH antagonist peptide, was evaluated in a Phase II clinical trial and showed a statistically significant reduction in fibroid size compared to placebo. Every other peptide discussed in community settings for fibroids, including BPC-157, TB-500, GHK-Cu, and Zhenoluten, has no fibroid-specific human trial data as of 2026. Their use for this condition is either theoretical or based on user-reported experience that has not been confirmed by imaging or controlled study.

Are these peptides legal to use for fibroids?

Cetrorelix is FDA-approved as a GnRH antagonist and has been used off-label in fibroid management under physician supervision. BPC-157, TB-500, and GHK-Cu are sold as research chemicals and are not approved for any human therapeutic use; their legal status for personal use varies by jurisdiction. Zhenoluten is available as a supplement or nutraceutical in some markets but is not FDA-approved as a fibroid treatment. None of the experimental peptides on this list can be legitimately prescribed via telemedicine for fibroid treatment under current FDA guidelines.

Could a peptide actually make fibroids worse?

Yes, and this is worth taking seriously. Research published in PNAS found that the peptide PrRP-31 increased proliferation in patient leiomyoma cells via the PI3K/AKT/MTOR signaling pathway, with this effect absent in normal uterine tissue. This does not mean all peptides carry that specific risk, but it demonstrates that peptides can interact with fibroid biology in unexpected and potentially harmful ways. That finding is a meaningful reason to be cautious about unmonitored experimental use in this context.

How long before any of these peptides might show results?

For cetrorelix, clinical protocols track outcomes over weeks to months, with the six-month ceiling set by bone density concerns rather than efficacy limits. For experimental options like BPC-157 and TB-500, community accounts describe symptom changes appearing within days to a few weeks, but those reports are subjective and unconfirmed by imaging. No established or validated timeline exists for the experimental compounds, and results across community reports have been highly variable from person to person.

Why do fibroid communities mention GLP-1 medications alongside peptides?

GLP-1 receptor agonists like semaglutide and tirzepatide are technically peptide-based drugs, which is likely why they surface in peptide-focused communities discussing fibroids. Some individuals have reported symptom changes, including pain reduction and in isolated cases apparent fibroid changes, while using these medications for other purposes. No peer-reviewed studies confirm GLP-1 efficacy for fibroid shrinkage, outcomes across community reports have been highly inconsistent, and any changes observed may reflect other concurrent treatments rather than a direct effect on fibroids.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for uterine fibroids in one place.